Loading…
← CockpitCompetitor Analysis › 688488.SS Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A688488.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum laggard 8
Mkt cap
$672M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$14.6M
20-day average traded
Fwd P/E
112.1×
forward earnings
ROIC−WACC
-2.7 pp
WACC 8.8%
Hurdle
+12 pp
Req g minus delivered
Next earnings
142 days
9 Apr 2027
Close · CNYCN¥10.59
1D-1.8%
1W-12.4%
1M-25.2%
3M-38.3%
6M-35.0%
YTD-35.1%
1Y-28.7%
ATR %6.7%
52w lowhigh53.0% off high

What Jiangsu Aidea Pharmaceutical does

Employees: 735

Jiangsu Aidea Pharmaceutical at a glance

Size Jiangsu Aidea Pharmaceutical (688488.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $672M, the 2984th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.59 on 18 Nov 2026.

Performance Over six months the shares fell 35.0%, against -6.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 7.1% over the last twelve months (peer median +11.6%); the operating margin is 7.9% (peer median 10.7%).

Valuation It trades at 112.1× forward earnings against a peer median of 17.0× (most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.7 points below its cost of capital (8.8% WACC).

Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 94688488.SS 66
Six months, rebased to 100: Jiangsu Aidea Pharmaceutical against the median of its 20 peers (local-currency closes).

Jiangsu Aidea Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥717MCN¥711MCN¥412MCN¥409MCN¥244M
Revenue growth—+73%+1%+68%—
Gross profitCN¥514MCN¥453MCN¥198MCN¥158MCN¥78.4M
EBITDAn/aCN¥89.6M-CN¥94.9M-CN¥58.3M-CN¥130M
Net incomeCN¥7.12M-CN¥19.5M-CN¥141M-CN¥76.1M-CN¥124M
Free cash flowCN¥1.50M-CN¥28.8M-CN¥77.9M-CN¥230M-CN¥224M
Capital expenditureCN¥67.6MCN¥47.9MCN¥44.6MCN¥71.2MCN¥140M
Total debtCN¥698MCN¥576MCN¥521MCN¥418MCN¥221M

Quarterly statements and history in the cockpit →

Jiangsu Aidea Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%PHILANNX688658600351SPARC0009154985FDCNVCTINNOVACAP000566300016412345343008780570ABUS603998SGMT688488.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Aidea Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%50×100×PHIL6886580009154985INNOVACAP3000164534603998688488.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Aidea Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%6003514985FDCINNOVACAP6008293000164123603998688488.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangsu Aidea Pharmaceutical is the large dot.

Jiangsu Aidea Pharmaceutical competitors and peer comparison

How Jiangsu Aidea Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Aidea Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688488.SSPeer medianRank in peer set
1-month return-25.2%-2.8%lowest of 21
6-month return-35.0%-6.0%2nd lowest of 21
Distance from 52-week high-53.0%-28.2%3rd lowest of 21
Revenue growth (TTM)+7.1%+11.6%8th lowest of 18
Operating margin7.9%10.7%7th lowest of 18
Forward P/E112.1×17.0×most expensive of 9
Growth the price implies (Req g, 7 yrs)31.9%6.5%2nd most demanding of 9
Growth delivered (Del g)+19.8%+7.1%2nd highest of 9
Hurdle (Req g minus delivered)+12.0 pp-0.6 pp3rd most demanding of 9
ROIC minus cost of capital-2.7 pp-0.0 pp7th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a

Questions

Which companies are Jiangsu Aidea Pharmaceutical's closest peers?
The cockpit's peer set: Philogen (PHIL.MI), Annexon (ANNX), Youcare Pharmaceutical (688658.SS), Yabao Pharmaceutical (600351.SS), Sun Pharma Advanced Research (SPARC.NS), Shandong Wit Dyne Health (000915.SZ), Earth (4985.T), FDC (FDC.NS).
Is Jiangsu Aidea Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 112.1× against a peer median of 17.0×, most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jiangsu Aidea Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -35.0% against -6.0% for the median peer; over one year -28.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.